Dr. Oliver Blanck is internationally recognized as an expert in the field of stereotactic radiotherapy and for cardiac radioablation (CR). After his graduation in 2008, Dr. Blanck joined CyberHeart (Sunnyvale, USA) as Senior Radiation Planning Engineer and ever since, one of his main research interested was focused on radiation treatments to the heart. From 2007-2010 CyberHeart performed ground laying pre-clinical research on atrial fibrillation (AF) and ventricular tachycardia (VT). Since 2010, Dr. Blanck has been working as head of operations, medical physics and research and development in two specialized radiosurgery centers in Güstrow/Kiel and Frankfurt am Main, Germany, which are associated with several university hospitals. In 2013 he finished his PhD thesis at the University of Lübeck on a pre-clinical dose-escalation study for cardiac radioablation while at the same time the first patients with VT were treated with CR in the USA and Europe. Between 2013 and 2018, Dr. Blanck focused his work on implementing multi-center trials on new indications for stereotactic radiotherapy in Germany and in 2019 the first patient in Germany with VT was treated with CR at the University Medical Center Schleswig-Holstein (Kiel, Germany) under his guidance. Soon thereafter the German multi-center study on Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias (RAVENTA) started. Dr. Blanck is a very active member in many national and international societies and leads the work-package on quality assurance for the EU Horizon 2020 project STOPStorm.